Thera-SAbDab

BLINATUMOMAB

>   Structural Summary
TherapeuticBlinatumomab
Target 1CD19
Heavy Chain 1QVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSS
Light Chain 1DIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNWYQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIK
100% seqID Fv 1 StructureNone
99% seqID Fv 1 StructureNone
95-98% seqID Fv 1 StructureNone
Target 2CD3E
Heavy Chain 2DIKLQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSS
Light Chain 2DIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELK
100% seqID Fv 2 StructureNone
99% seqID Fv 2 StructureNone
95-98% seqID Fv 2 StructureNone
>   Metadata
FormatBispecific T-Cell Engager
Isotypena
Highest Clinical Trial (Jan '20)Approved
Estimated Status (Jan '20)Active
Recorded Developmental TechnologyBiTE Technology
INN Year Proposed2008
INN Year Recommended2009
Companies InvolvedAmgen, Astellas Pharma, M. D. Anderson Cancer Center, Merck & Co, Micromet Inc, National Cancer Institute (USA), University of California Davis
Conditions ApprovedPrecursor B-cell lymphoblastic leukaemia-lymphoma
Conditions ActiveNon-Hodgkin's lymphoma, Diffuse large B cell lymphoma
Conditions DiscontinuedChronic lymphocytic leukaemia
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]